< >

HyperAcute Immunotherapy

NewLink Genetics has multiple HyperAcute immunotherapies currently under development in a variety of tumors

Phase 3 Trial in Pancreatic Cancer

Now enrolling patients with borderline resectable or locally advanced unresectable pancreatic cancer

Phase 2b/3 Trial in Lung Cancer

Now enrolling patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Investor Relations

Keep up with the latest news and presentations
NewLink Genetics to Host Its Second Quarter 2015 Earnings Conference Call on July 31, 2015
July 24, 2015

NewLink Genetics Announces That Dr. Thomas Monath Received Award From American Veterinary Epidemiology Society for Contributions to Public Health
July 22, 2015

ANNOUNCEMENTS